BIOMAT Database Logo BIOMAT Database Logo

Long-term tobramycin therapy in patients with cystic fibrosis and advanced pulmonary disease. 1979

U Paporisz, and H G Posselt, and R Wönne, and W Ristow, and D Röser, and H Knothe, and S W Bender

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008171 Lung Diseases Pathological processes involving any part of the LUNG. Pulmonary Diseases,Disease, Pulmonary,Diseases, Pulmonary,Pulmonary Disease,Disease, Lung,Diseases, Lung,Lung Disease
D011552 Pseudomonas Infections Infections with bacteria of the genus PSEUDOMONAS. Infections, Pseudomonas,Pseudomonas aeruginosa Infection,Infection, Pseudomonas,Pseudomonas Infection,Pseudomonas aeruginosa Infections
D003550 Cystic Fibrosis An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION. Mucoviscidosis,Cystic Fibrosis of Pancreas,Fibrocystic Disease of Pancreas,Pancreatic Cystic Fibrosis,Pulmonary Cystic Fibrosis,Cystic Fibrosis, Pancreatic,Cystic Fibrosis, Pulmonary,Fibrosis, Cystic,Pancreas Fibrocystic Disease,Pancreas Fibrocystic Diseases
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D014031 Tobramycin An aminoglycoside, broad-spectrum antibiotic produced by Streptomyces tenebrarius. It is effective against gram-negative bacteria, especially the PSEUDOMONAS species. It is a 10% component of the antibiotic complex, NEBRAMYCIN, produced by the same species. Nebramycin Factor 6,Brulamycin,Nebcin,Nebicin,Obracin,Tobracin,Tobramycin Sulfate,Sulfate, Tobramycin

Related Publications

U Paporisz, and H G Posselt, and R Wönne, and W Ristow, and D Röser, and H Knothe, and S W Bender
Long-term tobramycin aerosol therapy in cystic fibrosis.
January 1989, Pediatric pulmonology,
U Paporisz, and H G Posselt, and R Wönne, and W Ristow, and D Röser, and H Knothe, and S W Bender
Tobramycin therapy of pulmonary infections in patients with cystic fibrosis.
May 1974, Current therapeutic research, clinical and experimental,
U Paporisz, and H G Posselt, and R Wönne, and W Ristow, and D Röser, and H Knothe, and S W Bender
Tobramycin and ticarcillin therapy for exacerbations of pulmonary disease in patients with cystic fibrosis.
August 1976, The Journal of infectious diseases,
U Paporisz, and H G Posselt, and R Wönne, and W Ristow, and D Röser, and H Knothe, and S W Bender
Long-term tobramycin aerosol therapy of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.
January 1988, Scandinavian journal of gastroenterology. Supplement,
U Paporisz, and H G Posselt, and R Wönne, and W Ristow, and D Röser, and H Knothe, and S W Bender
The long-term use of inhaled tobramycin in patients with cystic fibrosis.
December 2002, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society,
U Paporisz, and H G Posselt, and R Wönne, and W Ristow, and D Röser, and H Knothe, and S W Bender
Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis.
January 2002, Chest,
U Paporisz, and H G Posselt, and R Wönne, and W Ristow, and D Röser, and H Knothe, and S W Bender
Long-term clinical outcomes of elexacaftor/tezacaftor/ivacaftor therapy in adults with cystic fibrosis and advanced pulmonary disease.
January 2023, Respiratory medicine,
U Paporisz, and H G Posselt, and R Wönne, and W Ristow, and D Röser, and H Knothe, and S W Bender
Long term azithromycin therapy in patients with cystic fibrosis.
January 2016, The Turkish journal of pediatrics,
U Paporisz, and H G Posselt, and R Wönne, and W Ristow, and D Röser, and H Knothe, and S W Bender
Long term nutritional rehabilitation by gastrostomy in Israeli patients with cystic fibrosis: clinical outcome in advanced pulmonary disease.
February 2006, Journal of pediatric gastroenterology and nutrition,
U Paporisz, and H G Posselt, and R Wönne, and W Ristow, and D Röser, and H Knothe, and S W Bender
Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa.
January 1989, Pediatric pulmonology,
Copied contents to your clipboard!